Recent Finacing
Recent Raise
ImmunityBio is a clinical-stage immunotherapy developer of immunotherapy and cell therapy platforms activating innate and adaptive immune responses; lead product N-803 (Anktiva) is developed with BCG for NMIBC.
Focus Areas
Recent Investors
Valuation as of 01/05/2019
Total Raised
Funding rounds
Investors
See the team members at ImmunityBio.
